FECAL-INTESTINAL MICROBIOTA TRANSPLANTATION: STATE OF THE ART AND CLINICAL CHALLENGES

Autores/as

  • Tiffani Casarin Autor
  • Isabela Yukari Sakai Autor
  • Manoel Armando Delgado Junior Autor
  • Kelly Cristina da Silva Brabes Autor

DOI:

https://doi.org/10.63330/aurumpub.034-025

Palabras clave:

Intestinal dysbiosis, Human microbiome, Microbiological therapy, Clostridioides difficile infection, Modulation of the gut microbiota

Resumen

The gut microbiota is a complex community of microorganisms that inhabit the human gastrointestinal tract and play essential roles in maintaining health, including participation in nutrient digestion, immune system modulation, metabolite production, and protection against pathogenic microorganisms. However, several factors, such as antibiotic use, dietary changes, environmental conditions, and hygiene practices, can compromise the balance of this microbial ecosystem, leading to dysbiosis. This condition is characterized by an imbalance between beneficial and potentially pathogenic microorganisms and is associated with the development of various diseases, including gastrointestinal disorders, metabolic, inflammatory, autoimmune, and neurological diseases. In this context, fecal microbiota transplantation (FMT) has emerged as a promising therapeutic strategy to restore the balance of the gut microbiota. This technique consists of transferring fecal material from a healthy donor to the gastrointestinal tract of a recipient, with the aim of restoring microbial diversity and functionality. The procedure can be performed via different administration routes, such as colonoscopy, enemas, nasogastric tubes, or oral capsules, with the latter two and colonoscopy being associated with better therapeutic results. MFT (Metabolic Transplantation) shows high efficacy in the treatment of recurrent Clostridioides difficile infections, with high cure rates reported in the literature. Furthermore, recent studies are investigating its therapeutic potential in other conditions associated with dysbiosis, such as irritable bowel syndrome, inflammatory bowel diseases, obesity, type 2 diabetes, and neurodegenerative diseases. Despite advances, the clinical application of MFT still faces challenges related to the standardization of protocols, rigorous donor selection, microbiological safety of the transplanted material, and monitoring of long-term effects. Therefore, more studies are needed to consolidate this approach as a safe and widely applicable therapeutic strategy in clinical practice.

Descargas

Los datos de descarga aún no están disponibles.

Referencias

ALAEDDIN, S. et al. Exploring the effects of faecal microbiota transplantation on cognitive function: A review of clinical trials. Brain, Behavior, & Immunity - Health, v. 48, n. 101049, 2025. DOI: https://doi.org/10.1016/j.bbih.2025.101049

BASKE, M. M. et al. Fecal microbiota transplant on Escherichia-Shigella gut composition and its potential role in the treatment of generalized anxiety disorder: a systematic review. Journal of Affective Disorders, v. 354, 2024. DOI: https://doi.org/10.1016/j.jad.2024.03.088

CHAVES, J. F. O.; RONCOLATO, M. C. D. S. Transplante de microbiota fecal no tratamento de infecções recorrentes por Clostridioides difficile. Asclepius International Journal of Scientific Health Science, v. 4, n. 5, 2025. DOI: https://doi.org/10.70779/aijshs.v4i5.137

CHEN, C. et al. Novel alginate formulation for fecal microbiota transplantation: comparative and long-term stability evaluation. Journal of Drug Delivery Science and Technology, v. 115, n. 107700, 2026. DOI: https://doi.org/10.1016/j.jddst.2025.107700

HAUSER, G. et al. Intestinal microbiota modulation by fecal microbiota transplantation in nonalcoholic fatty liver disease. Biomedicines, v. 13, n. 4, 2025. DOI: https://doi.org/10.3390/biomedicines13040779

HOU, S. et al. Advances in fecal microbiota transplantation for gut dysbiosis-related diseases. Advanced Science, v. 12, n. 13, 2025. DOI: https://doi.org/10.1002/advs.202413197

LIU, L. et al. Relationship between pediatric asthma and respiratory microbiota, intestinal microbiota: a narrative review. Frontiers in Microbiology, v. 16, 2025. DOI: https://doi.org/10.3389/fmicb.2025.1550783

MAIA, M. C.; PEREIRA, M. C. M.; SCHACHTER, D. C. Uma revisão bibliográfica sobre o eixo cérebro-intestino-microbiota na doença de Alzheimer. Brazilian Journal of Health Review, v. 8, n. 3, 2025. DOI: https://doi.org/10.34119/bjhrv8n3-281

NEMZER, B. V. et al. Health-improving effects of polyphenols on the human intestinal microbiota: a review. International Journal of Molecular Sciences, v. 26, n. 3, 2025. DOI: https://doi.org/10.3390/ijms26031335

PETERLE, L. M. et al. A interligação entre microbiota intestinal alterada e transtornos do espectro autista: uma revisão sistemática. Brazilian Journal of Implantology and Health Sciences, v. 7, n. 1, 2025. DOI: https://doi.org/10.36557/2674-8169.2025v7n1p1631-1647

RAHMAN, R.; MARCOLLA, C. S.; WILLING, B. P. Fecal microbiota transplantation in pigs: current status and future perspective. Animal Microbiome, v. 7, n. 1, 2025. DOI: https://doi.org/10.1186/s42523-025-00440-w

REN, J. et al. Fecal Microbiota Transplantation in Alzheimer’s Disease: Mechanistic Insights Through the Microbiota–Gut–Brain Axis and Therapeutic Prospects. Microorganisms, v. 13, n. 8, 2025. DOI: https://doi.org/10.3390/microorganisms13081956

SALA, L. et al. The eternal struggle between titans: fecal microbiota transplant (FMT) versus metformin in type 2 diabetes (T2D) gut dysmotility. Journal of Advanced Research, 2025. DOI: https://doi.org/10.1016/j.jare.2025.09.021

YANG, K. et al. Distribution of gut microbiota across intestinal segments and their impact on human physiological and pathological processes. Cell and Bioscience, v. 15, n. 1, 2025. DOI: https://doi.org/10.1186/s13578-025-01385-y

ZHOU, Y. et al. Human fecal microbiota transplantation attenuates high dietary oxalate-induced renal calcium oxalate crystal depositions in rats via repairing Allobaculum-related gut barrier damage. mSystems, v. 10, n. 9, 2025. DOI: https://doi.org/10.1128/msystems.00810-25

Publicado

2026-03-17

Número

Sección

Artigos

Cómo citar

Casarin, T., Sakai, I. Y., Delgado Junior, M. A., & Brabes, K. C. da S. (2026). FECAL-INTESTINAL MICROBIOTA TRANSPLANTATION: STATE OF THE ART AND CLINICAL CHALLENGES. Aurum Editora, 338-351. https://doi.org/10.63330/aurumpub.034-025